Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.3200
0.026.31%
Pre-Market: 7:03 AM EDT
Comments
Loading...
Athira Pharma Analyst Ratings and Price Targets | NASDAQ:ATHA | Benzinga
Athira Pharma Inc has a consensus price target of $12.7 based on the ratings of 7 analysts. The high is $33 issued by Berenberg on April 21, 2022. The low is $0.5 issued by Mizuho on September 19, 2024. The 3 most-recent analyst ratings were released by Mizuho, Rodman & Renshaw, and JMP Securities on September 19, 2024, August 19, 2024, and June 20, 2024, respectively. With an average price target of $13.83 between Mizuho, Rodman & Renshaw, and JMP Securities, there's an implied 4222.92% upside for Athira Pharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Mizuho
Rodman & Renshaw
Stifel
Jefferies
Berenberg
1calculated from analyst ratings
Analyst Ratings for Athira Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 09/19/2024 | Buy Now | 56.25% | Mizuho | Graig Suvannavejh54% | $5 → $0.5 | Downgrade | Outperform → Neutral | Get Alert |
| 09/04/2024 | Buy Now | — | JMP Securities | Jason Butler56% | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 09/04/2024 | Buy Now | — | BTIG | Thomas Shrader43% | — | Downgrade | Buy → Neutral | Get Alert |
| 08/19/2024 | Buy Now | 6775% | Rodman & Renshaw | Elemer Piros55% | → $22 | Initiates | → Buy | Get Alert |
| 06/20/2024 | Buy Now | 5837.5% | JMP Securities | Jason Butler56% | $19 → $19 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/16/2024 | Buy Now | 5837.5% | JMP Securities | Jason Butler56% | $19 → $19 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/11/2023 | Buy Now | 5837.5% | JMP Securities | Jason Butler56% | $20 → $19 | Maintains | Outperform | Get Alert |
| 05/15/2023 | Buy Now | 1462.5% | Mizuho | Graig Suvannavejh54% | $6 → $5 | Maintains | Buy | Get Alert |
| 03/30/2023 | Buy Now | 3025% | BTIG | Thomas Shrader43% | $33 → $10 | Maintains | Buy | Get Alert |
| 03/24/2023 | Buy Now | 6150% | JMP Securities | Jason Butler56% | → $20 | Reiterates | → Market Outperform | Get Alert |
| 07/07/2022 | Buy Now | 1775% | Mizuho | Graig Suvannavejh54% | → $6 | Initiates | → Buy | Get Alert |
| 06/23/2022 | Buy Now | 1462.5% | Stifel | Paul Matteis43% | $36 → $5 | Downgrade | Buy → Hold | Get Alert |
| 06/23/2022 | Buy Now | — | JMP Securities | Jason Butler56% | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 06/23/2022 | Buy Now | 837.5% | Jefferies | Andrew Tsai29% | $32 → $3 | Downgrade | Buy → Hold | Get Alert |
| 05/10/2022 | Buy Now | 10212.5% | BTIG | Thomas Shrader43% | → $33 | Initiates | → Buy | Get Alert |
| 04/21/2022 | Buy Now | 10212.5% | Berenberg | Esther Hong19% | → $33 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Athira Pharma (ATHA) stock?
The latest price target for Athira Pharma (NASDAQ:ATHA) was reported by Mizuho on September 19, 2024. The analyst firm set a price target for $0.50 expecting ATHA to rise to within 12 months (a possible 56.25% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Athira Pharma (ATHA)?
The latest analyst rating for Athira Pharma (NASDAQ:ATHA) was provided by Mizuho, and Athira Pharma downgraded their neutral rating.
When was the last upgrade for Athira Pharma (ATHA)?
There is no last upgrade for Athira Pharma
When was the last downgrade for Athira Pharma (ATHA)?
The last downgrade for Athira Pharma Inc happened on September 19, 2024 when Mizuho changed their price target from $5 to $0.5 for Athira Pharma Inc.
When is the next analyst rating going to be posted or updated for Athira Pharma (ATHA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Athira Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Athira Pharma was filed on September 19, 2024 so you should expect the next rating to be made available sometime around September 19, 2025.
Is the Analyst Rating Athira Pharma (ATHA) correct?
While ratings are subjective and will change, the latest Athira Pharma (ATHA) rating was a downgraded with a price target of $5.00 to $0.50. The current price Athira Pharma (ATHA) is trading at is $0.32, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.